CareDx Stock News

CareDx Expands Transplant Portfolio in Europe CareDx Expands Transplant Portfolio in Europe

Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes

CareDx, Inc (NASDAQ:CDNA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Ian Cooney - VP of IR Reg Seeto - CEO Ankur Dhingra - CFO Conference Call Participants Alex Nowa

CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Transplants are in high demand; this company is making the process of getting one smoother.

Transplants are in high demand; this company is making the process of getting one smoother.

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically dif

CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients CareDx CEO and President, Reg Seeto, Joins I

Upgrades RBC Capital upgraded the previous rating for United States Steel Corp (NYSE:X) from Sector Perform to Outperform. United States Steel earned $3.64 in the fourth quarter, compared to $0.27 in

CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR

SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d

Data Highlights Clinical Utility of CareDx Solutions, Including Findings from Surveillance HeartCare Outcomes Registry (SHORE) Demonstrating Power of Multimodality Assessment for More Precise Interven

CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States CareDx Testing Services Have Been Used in Over 30,000 Heart Transpla